Table 3.
Sites of Treatment Failure According to Clinical Features of Cervical Cancer and Treatment
| Features | Treatment failure | |||
|---|---|---|---|---|
| Total | Loco-regional | Systemic | Loco-regional and systemic | |
| Age group | ||||
| ≤ 40 years | 14 | 6 (42.9) | 5 (35.7) | 3 (21.4) |
| > 40 years | 71 | 39 (54.9) | 21 (29.6) | 11 (15.5) |
| FIGO 2018 stage | ||||
| IIB | 30 | 14 (46.7) | 12 (40) | 4 (13.3) |
| IIIA | 2 | 1 (50) | 1 (50) | - |
| IIIB | 20 | 10 (50) | 4 (20) | 6 (30) |
| IIIC1r | 31 | 19 (61.3) | 9 (29) | 3 (9.7) |
| IVA | 2 | 1 (50) | - | 1 (50) |
| Histology | ||||
| SCC | 59 | 33 (55.9) | 17 (28.8) | 9 (15.3) |
| ACA/ AS | 26 | 12 (46.2) | 9 (34.6) | 5 (19.2) |
| Tumor size | ||||
| ≤ 4 cm. | 23 | 13 (56.5) | 7 (30.4) | 3 (13) |
| > 4 cm. | 62 | 32 (51.6) | 19 (30.6) | 11 (17.7) |
| Total radiation dose | ||||
| Total dose <85 Gy | 14 | 12 (85.7) | - | 2 (14.3) |
| Total dose ≥85 Gy | 71 | 33 (46.5) | 26 (36.6) | 12 (16.9) |
| Total treatment times | ||||
| ≤ 56 days | 39 | 22 (56.4) | 10 (25.6) | 7 (17.9) |
| >56 Days | 46 | 23 (50) | 16 (34.8) | 7 (15.2) |
| Brachytherapy techniques | ||||
| 2D Planning | 63 | 31 (49.2) | 22 (34.9) | 10 (15.9) |
| 3D Planning | 22 | 14 (63.6) | 4 (18.2) | 4 (18.2) |
| Cisplatin cycle | ||||
| <5 cycles | 24 | 18 (75) | 3 (12.5) | 3 (12.5) |
| ≥ 5 cycles | 61 | 27 (44.3) | 23 (37.7) | 11 (18) |
| Cisplatin total dose | ||||
| <200 mg | 22 | 18 (81.8) | 2 (9.1) | 2 (9.1) |
| ≥200 mg | 63 | 27 (42.9) | 24 (38.1) | 12 (19) |